NEW YORK (GenomeWeb) – Molecular diagnostics firm ImmunArray announced that it has received a $10 million Series B investment from private investment firm Exigent Capital.
Other details of the financing were not disclosed.
The firm, which is based in Israel and Virginia, markets blood-based tests based on its iChip antibody-detecting microarray technology. So far, it has developed a six-biomarker panel for ruling out systemic lupus erythematosus and is developing tests for traumatic brain injury and immuno-oncology. The iChip platform can print proteins and peptides, short sequences of nucleotides and DNA, as well as cell surface receptors, cytokines, chemokines, and even lipid or carbohydrate-based molecules.
The funding will help the firm "accelerate and expand our commercial infrastructure, widen our reach into lupus-related products, and broaden our work into other autoimmune diseases," said CEO Donna Edmonds in a statement, adding that the money would help the firm move toward commercializing its brain injury tests.